SCYX - Scynexis: Leading The Yeast Infection Treatment Industry
- SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections.
- BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal class in the past 20+ years.
- The drug has ten years of market regulatory exclusivity and patent protection until 2035.
- The company’s financial position is robust, with adequate cash to commercialize BREXAFEMME while continuing its current studies.
For further details see:
Scynexis: Leading The Yeast Infection Treatment Industry